These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23106277)

  • 1. Targeting the mycobacterial envelope for tuberculosis drug development.
    Favrot L; Ronning DR
    Expert Rev Anti Infect Ther; 2012 Sep; 10(9):1023-36. PubMed ID: 23106277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus.
    Nataraj V; Varela C; Javid A; Singh A; Besra GS; Bhatt A
    Mol Microbiol; 2015 Oct; 98(1):7-16. PubMed ID: 26135034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis.
    de Souza MV; Ferreira Mde L; Pinheiro AC; Saraiva MF; de Almeida MV; Valle MS
    ScientificWorldJournal; 2008 Jul; 8():720-51. PubMed ID: 18677428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.
    North EJ; Jackson M; Lee RE
    Curr Pharm Des; 2014; 20(27):4357-78. PubMed ID: 24245756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Antibacterial β-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis.
    Lehmann J; Cheng TY; Aggarwal A; Park AS; Zeiler E; Raju RM; Akopian T; Kandror O; Sacchettini JC; Moody DB; Rubin EJ; Sieber SA
    Angew Chem Int Ed Engl; 2018 Jan; 57(1):348-353. PubMed ID: 29067779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design.
    Singh G; Kumar A; Maan P; Kaur J
    Curr Drug Targets; 2017 Nov; 18(16):1904-1918. PubMed ID: 28699515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis.
    Schroeder EK; de Souza N; Santos DS; Blanchard JS; Basso LA
    Curr Pharm Biotechnol; 2002 Sep; 3(3):197-225. PubMed ID: 12164478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis.
    Bhat ZS; Rather MA; Maqbool M; Lah HU; Yousuf SK; Ahmad Z
    Biomed Pharmacother; 2017 Nov; 95():1520-1534. PubMed ID: 28946393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MmpL3 inhibitors as antituberculosis drugs.
    Shao M; McNeil M; Cook GM; Lu X
    Eur J Med Chem; 2020 Aug; 200():112390. PubMed ID: 32447196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional evidence that lipoprotein LpqN supports cell envelope biogenesis in
    Melly GC; Stokas H; Dunaj JL; Hsu FF; Rajavel M; Su CC; Yu EW; Purdy GE
    J Biol Chem; 2019 Oct; 294(43):15711-15723. PubMed ID: 31471317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.
    Fay A; Czudnochowski N; Rock JM; Johnson JR; Krogan NJ; Rosenberg O; Glickman MS
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial drugs: hitting the tuberculosis wall.
    Harrison C
    Nat Rev Drug Discov; 2013 Aug; 12(8):578-9. PubMed ID: 23903215
    [No Abstract]   [Full Text] [Related]  

  • 14. Insight into Structure-Function Relationships and Inhibition of the Fatty Acyl-AMP Ligase (FadD32) Orthologs from Mycobacteria.
    Guillet V; Galandrin S; Maveyraud L; Ladevèze S; Mariaule V; Bon C; Eynard N; Daffé M; Marrakchi H; Mourey L
    J Biol Chem; 2016 Apr; 291(15):7973-89. PubMed ID: 26900152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
    Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MmpL3 for anti-tuberculosis drug development.
    Bolla JR
    Biochem Soc Trans; 2020 Aug; 48(4):1463-1472. PubMed ID: 32662825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins.
    Bardou F; Quémard A; Dupont MA; Horn C; Marchal G; Daffé M
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2459-67. PubMed ID: 8913447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development.
    Bhatt A; Molle V; Besra GS; Jacobs WR; Kremer L
    Mol Microbiol; 2007 Jun; 64(6):1442-54. PubMed ID: 17555433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 20. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.
    Alahari A; Trivelli X; Guérardel Y; Dover LG; Besra GS; Sacchettini JC; Reynolds RC; Coxon GD; Kremer L
    PLoS One; 2007 Dec; 2(12):e1343. PubMed ID: 18094751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.